Efficacy and Safety of Anti–B-Cell Maturation Antigen Chimeric Antigen Receptor T-Cell for the Treatment of Relapsed and Refractory AL Amyloidosis
Journal of Clinical Oncology · 10.06.2025 · 43 (17) · 2007-2016
DOI: 10.1200/jco-24-02252 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Journal of Clinical Oncology, erschienen am 10.06.2025. Verfasst von Eyal Lebel und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Bone Marrow Transplantation and Cancer Immunotherapy, Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Jer…. Hauptthemen laut MEDLINE: Immunoglobulin Light-chain Amyloidosis, B-Cell Maturation Antigen, Receptors, Chimeric Antigen, Immunotherapy, Adoptive. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 33 Literaturangaben.
Abstract (Originalsprache)
PURPOSE The use of anti–B-cell maturation antigen (BCMA) chimeric antigen receptor T-cell (CART) therapy for AL amyloidosis (AL) is limited owing to patient frailty. HBI0101 anti-BCMA CART was the first proof of concept for its applicability to AL. This report addresses the AL patient cohort treated to date within the phase Ia/Ib clinical trial (ClinicalTrials.gov identifier: NCT04720313 ). METHODS After lymphodepletion, most AL patients were infused with 800 × 10 6 CARTs. RESULTS Sixteen patients were treated, with a median of four previous lines of therapy (range, 3-10), 14/16 were triple class refractory, and 6/16 were refractory to belantamab. Most patients (13/16) had cardiac involvement, including five with MAYO stage IIIa/IIIb at study entry. Cytokine release syndrome was frequent (14/16) but mostly low grade (grade 3: 3/16, no grade 4/5). No neurologic toxicity or treatment-related deaths were observed. There were five grade 3 AL-related organ deteriorations resolved quickly with supportive care. The overall hematologic response rate was 15/16 (94%) and complete response (CR) was 12/16 (75%). Minimal residual disease negativity was achieved in 9/14 evaluable patients. Most patients (8/13 evaluable) achieved an objective organ response. Seven patients died during long-term follow-up, three while in CR/very good partial response, and the median overall survival was 10.1 months (95% CI, 5.8 to not reached). CONCLUSION This largest clinical trial of AL patients treated with anti-BCMA CART demonstrates acceptable and manageable toxicity in a highly frail and resistant population with remarkable efficacy, leading to fast organ responses. Among patients with baseline advanced cardiac disease, deaths in the first year were frequent, suggesting that this effective therapy should be considered earlier in the course of therapy. Anti-BCMA CART may become a powerful tool for improving organ function and survival in patients with AL.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Bone Marrow Transplantation and Cancer Immunotherapy, Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.
- Department of Hematology, Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.
- Department of Hematology, Tel Aviv Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
- Laboratory of Tumor Immunology and Immunotherapy, The Mina and Everard Goodman Faculty of Life Sciences, Bar-Ilan University, Ramat Gan, Israel.
ORCID-Profile: Eyal Lebel, Nathalie Asherie, Marjorie Pick, Shlomit Herr, Cyrille Cohen, Moshe E Gatt
Zitieren
APA
Lebel, E., Asherie, N., Kfir-Erenfeld, S., Grisariu, S., Avni, B., Elias, S., Assayag, M., Dubnikov-Sharon, T., Pick, M., Alexander-Shani, R., Bessig, N., Herr, S., Shehadeh, A., Ishtay, A., Pimienta, S., Vainstein, V., Zimran, E., Cohen, Y., Avivi, I., …, & Gatt, M. E. (2025). Efficacy and Safety of Anti–B-Cell Maturation Antigen Chimeric Antigen Receptor T-Cell for the Treatment of Relapsed and Refractory AL Amyloidosis. Journal of Clinical Oncology, 43(17), 2007-2016. https://doi.org/10.1200/jco-24-02252
Vancouver
Lebel E, Asherie N, Kfir-Erenfeld S, Grisariu S, Avni B, Elias S, et al. Efficacy and Safety of Anti–B-Cell Maturation Antigen Chimeric Antigen Receptor T-Cell for the Treatment of Relapsed and Refractory AL Amyloidosis. Journal of Clinical Oncology. 2025;43(17):2007-2016. doi:10.1200/jco-24-02252
BibTeX
@article{Lebel2025,
author = {Lebel, Eyal and Asherie, Nathalie and Kfir-Erenfeld, Shlomit and Grisariu, Sigal and Avni, Batia and Elias, Shlomo and Assayag, Miri and Dubnikov-Sharon, Tali and Pick, Marjorie and Alexander-Shani, Rivka and Bessig, Nomi and Herr, Shlomit and Shehadeh, Alaa and Ishtay, Aseel and Pimienta, Shelly and Vainstein, Vladimir and Zimran, Eran and Cohen, Yael and Avivi, Irit and Cohen, Cyrille and Stepensky, Polina and Gatt, Moshe E},
title = {Efficacy and Safety of Anti–B-Cell Maturation Antigen Chimeric Antigen Receptor T-Cell for the Treatment of Relapsed and Refractory AL Amyloidosis},
journal = {Journal of Clinical Oncology},
year = {2025},
volume = {43},
number = {17},
pages = {2007--2016},
doi = {10.1200/jco-24-02252}
}
EUVIMED